1-15 of 15
Richard Piekarz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C

Mark H. O’Hara, Opeyemi Jegede, Mark A. Dickson, Angela M. DeMichele, Richard Piekarz, Robert J. Gray, Victoria Wang, Lisa M. McShane, Lawrence V. Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Adedayo Onitilo, James V. Tricoli, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O’Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 56–64.
https://doi.org/10.1158/1078-0432.CCR-24-0036
Published: 06 January 2025
View article titled, Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C
Open the PDF for Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma

John A. Ligon, R. Taylor Sundby, Mary F. Wedekind, Fernanda I. Arnaldez, Jaydira Del Rivero, Lori Wiener, Ramaprasad Srinivasan, Melissa Spencer, Amanda Carbonell, Haiyan Lei, John Shern, Seth M. Steinberg, William D. Figg, Cody J. Peer, Sara Zimmerman, Josquin Moraly, Xia Xu, Stephen Fox, King Chan, Michael I. Barbato, Thorkell Andresson, Naomi Taylor, Karel Pacak, J. Keith Killian, Eva Dombi, W. Marston Linehan, Markku Miettinen, Richard Piekarz, Lee J. Helman, Paul Meltzer, Brigitte Widemann, John Glod
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (2): 341–348.
https://doi.org/10.1158/1078-0432.CCR-22-2168
Published: 17 January 2023
View article titled, A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Open the PDF for A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Report of the First International Symposium on NUT Carcinoma

Christopher A. French, Michael L. Cheng, Glenn J. Hanna, Steven G. DuBois, Nicole G. Chau, Christine L. Hann, Simone Storck, Ravi Salgia, Matteo Trucco, Jennifer Tseng, Anastasios Stathis, Richard Piekarz, Ulrich M. Lauer, Christophe Massard, Kelly Bennett, Shodeinde Coker, Ulrike Tontsch-Grunt, Martin L. Sos, Sida Liao, Catherine J. Wu, Kornelia Polyak, Sarina A. Piha-Paul, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2493–2505.
https://doi.org/10.1158/1078-0432.CCR-22-0591
Published: 13 June 2022
View article titled, Report of the First International Symposium on NUT Carcinoma
Open the PDF for Report of the First International Symposium on NUT Carcinoma in another window
Journal Articles

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas

Geraldine O'Sullivan Coyne, Shivaani Kummar, James Hu, Kristen Ganjoo, Warren A. Chow, Khanh T. Do, Jennifer Zlott, Ashley Bruns, Lawrence Rubinstein, Jared C. Foster, Lamin Juwara, Robert Meehan, Richard Piekarz, Howard Streicher, Elad Sharon, Naoko Takebe, Andrea Regier Voth, Donald Bottaro, Rene Costello, John J. Wright, James H. Doroshow, Alice P. Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 279–288.
https://doi.org/10.1158/1078-0432.CCR-21-2480
Published: 15 January 2022
View article titled, Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
Open the PDF for Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844)

Evanthia T. Roussos Torres, Christine Rafie, Chenguang Wang, David Lim, Adam Brufsky, Patricia LoRusso, Joseph Paul Eder, Vincent Chung, Melinda Downs, Molly Geare, Richard Piekarz, Howard Streicher, Leslie Anforth, Michelle A. Rudek, Qingfeng Zhu, Sepideh Besharati, Ashley Cimino-Mathews, Robert A. Anders, Vered Stearns, Elizabeth M. Jaffee, Roisin M. Connolly
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5828–5837.
https://doi.org/10.1158/1078-0432.CCR-20-5017
Published: 01 November 2021
View article titled, Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844)
Open the PDF for Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844) in another window
Includes: Supplementary data
Journal Articles

Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

Naoko Takebe, Abdul Rafeh Naqash, Geraldine O'Sullivan Coyne, Shivaani Kummar, Khanh Do, Ashley Bruns, Lamin Juwara, Jennifer Zlott, Larry Rubinstein, Richard Piekarz, Elad Sharon, Howard Streicher, Arjun Mittra, Sarah B. Miller, Jiuping Ji, Deborah Wilsker, Robert J. Kinders, Ralph E. Parchment, Li Chen, Ting-Chia Chang, Biswajit Das, Ganesh Mugundu, James H. Doroshow, Alice P. Chen
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (14): 3834–3844.
https://doi.org/10.1158/1078-0432.CCR-21-0329
Published: 15 July 2021
View article titled, Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
Open the PDF for Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response

Linda R. Duska, Virginia L. Filiaci, Joan L. Walker, Laura L. Holman, Emily K. Hill, Richard G. Moore, Kari L. Ring, Michael L. Pearl, Carolyn Y. Muller, Christina L. Kushnir, Heather A. Lankes, Megan I. Samuelson, Kelley S. Carrick, Anand Rajan, William H. Rodgers, Elise C. Kohn, Richard Piekarz, Kimberly K. Leslie
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (10): 2734–2741.
https://doi.org/10.1158/1078-0432.CCR-20-4618
Published: 15 May 2021
View article titled, A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response
Open the PDF for A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response in another window
Journal Articles

Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Roisin M. Connolly, Eric Laille, Ulka Vaishampayan, Vincent Chung, Karen Kelly, Afshin Dowlati, Olatunji B. Alese, R. Donald Harvey, Paul Haluska, Lillian L. Siu, Shivaani Kummar, Richard Piekarz, S. Percy Ivy, Nicole M. Anders, Melinda Downs, Ashley O'Connor, Angela Scardina, Jacqueline Saunders, Gary L. Rosner, Michael A. Carducci, Michelle A. Rudek
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5329–5337.
https://doi.org/10.1158/1078-0432.CCR-20-1412
Published: 15 October 2020
View article titled, Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Open the PDF for Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study in another window
Journal Articles

Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870)

Roberto Pili, David I. Quinn, Hans J. Hammers, Paul Monk, Saby George, Tanya B. Dorff, Thomas Olencki, Li Shen, Ashley Orillion, Dominick Lamonica, Roberto S. Fragomeni, Zsolt Szabo, Alan Hutson, Adrienne Groman, Susan M. Perkins, Richard Piekarz, Michael A. Carducci
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (23): 7199–7208.
https://doi.org/10.1158/1078-0432.CCR-17-1178
Published: 30 November 2017
View article titled, Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870)
Open the PDF for Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870) in another window
Includes: Supplementary data
Journal Articles

Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies

Shailly Mehrotra, Mathangi Gopalakrishnan, Jogarao Gobburu, Jiuping Ji, Jacqueline M. Greer, Richard Piekarz, Judith E. Karp, Keith W. Pratz, Michelle A. Rudek
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (21): 6421–6429.
https://doi.org/10.1158/1078-0432.CCR-17-0143
Published: 31 October 2017
View article titled, Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies
Open the PDF for Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies in another window
Includes: Supplementary data
Journal Articles

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083

George Somlo, Paul H. Frankel, Banu K. Arun, Cynthia X. Ma, Agustin A. Garcia, Tessa Cigler, Leah V. Cream, Harold A. Harvey, Joseph A. Sparano, Rita Nanda, Helen K. Chew, Timothy J. Moynihan, Linda T. Vahdat, Matthew P. Goetz, Jan H. Beumer, Arti Hurria, Joanne Mortimer, Richard Piekarz, Sharon Sand, Josef Herzog, Lily R. Van Tongeren, Katherine V. Ferry-Galow, Alice P. Chen, Christopher Ruel, Edward M. Newman, David R. Gandara, Jeffrey N. Weitzel
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4066–4076.
https://doi.org/10.1158/1078-0432.CCR-16-2714
Published: 01 August 2017
View article titled, Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <em>BRCA1</em>- or <em>BRCA2</em>-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
Open the PDF for Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <em>BRCA1</em>- or <em>BRCA2</em>-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083 in another window
Includes: Supplementary data
Journal Articles

Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

Roisin M. Connolly, Huili Li, Rachel C. Jankowitz, Zhe Zhang, Michelle A. Rudek, Stacie C. Jeter, Shannon A. Slater, Penny Powers, Antonio C. Wolff, John H. Fetting, Adam Brufsky, Richard Piekarz, Nita Ahuja, Peter W. Laird, Hui Shen, Daniel J. Weisenberger, Leslie Cope, James G. Herman, George Somlo, Agustin A. Garcia, Peter A. Jones, Stephen B. Baylin, Nancy E. Davidson, Cynthia A. Zahnow, Vered Stearns
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11): 2691–2701.
https://doi.org/10.1158/1078-0432.CCR-16-1729
Published: 31 May 2017
View article titled, Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study
Open the PDF for Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent

Leonard J. Appleman, Sanjeeve Balasubramaniam, Robert A. Parise, Christine Bryla, Christophe E. Redon, Asako J. Nakamura, William M. Bonner, John J. Wright, Richard Piekarz, David R. Kohler, Yixing Jiang, Chandra P. Belani, Julie Eiseman, Edward Chu, Jan H. Beumer, Susan E. Bates
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4): 721–729.
https://doi.org/10.1158/1078-0432.CCR-14-1333
Published: 16 February 2015
View article titled, A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent
Open the PDF for A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study

Anish Thomas, Arun Rajan, Eva Szabo, Yusuke Tomita, Corey A. Carter, Barbara Scepura, Ariel Lopez-Chavez, Min-Jung Lee, Christophe E. Redon, Ari Frosch, Cody J. Peer, Yuanbin Chen, Richard Piekarz, Seth M. Steinberg, Jane B. Trepel, William D. Figg, David S. Schrump, Giuseppe Giaccone
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (21): 5392–5402.
https://doi.org/10.1158/1078-0432.CCR-14-0968
Published: 30 October 2014
View article titled, A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study
Open the PDF for A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study in another window
Includes: Supplementary data
Journal Articles

Abstract B9: Activated MAPK Pathway Mediates Resistance to Romidepsin via Bim Degradation in Romidepsin-Selected HuT 78 Cells

Arup Chakraborty, Robert Robey, Jean-Pierre Gillet, Victoria Luchenko, Richard Piekarz, Michael Gottesman, Nathan Collie, Susan Bates
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): B9.
https://doi.org/10.1158/1078-0432.MECHRES-B9
Published: 04 March 2013
View article titled, Abstract B9: Activated MAPK Pathway Mediates Resistance to Romidepsin via Bim Degradation in Romidepsin-Selected HuT 78 Cells
Open the PDF for Abstract B9: Activated MAPK Pathway Mediates Resistance to Romidepsin via Bim Degradation in Romidepsin-Selected HuT 78 Cells in another window